Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 8/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.46 |
| ▸ | MGLL | Q99685 | 9/20 | 0.45 |
| ▸ | FAAH | O00519 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16405262 | 0.86 | MGLL (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL29044909 | 0.86 | MGLL (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL18085753 | 0.85 | PTGS1 (0.36) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL17570363 | 0.80 | PTGS1 (0.48) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL16405264 | 0.80 | PTGS1 (0.63) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL19546603 | 0.78 | MGLL (0.52) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL31038302 | 0.77 | PTGS1 (0.46) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL17903047 | 0.76 | MGLL (0.45) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL4761432 | 0.76 | ALDH1A1 (0.50) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL13642670 | 0.73 | PTGS1 (0.46) | PTGS1PTGS2MGLLFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-9796766-B2 | Potent and selective inhibitors of NAV1.3 and NAV1.7 | AMGEN INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9636418-B2 | Potent and selective inhibitors of NAV1.7 | AMGEN INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170107255-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160304570-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9340590-B2 | Potent and selective inhibitors of NaV1.3 and NaV1.7 | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160067347-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160024159-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | AMGEN INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150023988-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | AMGEN INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130209466-A1 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS | AMGEN INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8420779-B2 | Compositions and methods for producing bioactive fusion proteins | AMGEN INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8288351-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8278280-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120121591-A1 | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7605120-B2 | peptides and/or conjugated peptides may be used as therapeutics or prophylactics for the treatment of diseases mediated by B1 activation, including inflammation and chronic pain states of inflammatory and neuropathic origin, septic shock, arthritis, osteoarthritis, angina, asthma, allergic rhinitis | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | AMGEN INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | PTGS1 220/4885PTGS2 654/4885MGLL 2155/4885 |
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | HGFAC, HDGF, GRB2 | PTGS1 4059/4885PTGS2 4404/4885MGLL 4489/4885 |
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | PTGS1 3181/4885PTGS2 3564/4885MGLL 4473/4885 |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | PTGS1 389/4885PTGS2 817/4885MGLL 2515/4885 |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, AVPR1B | PTGS1 296/4885PTGS2 664/4885MGLL 3049/4885 |
| US-20130209466-A1 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS | HGFAC, HDGF, GRB2 | PTGS1 4059/4885PTGS2 4404/4885MGLL 4489/4885 |
| US-20170107255-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | PTGS1 3535/4885PTGS2 3850/4885MGLL 3340/4885 |
| US-20120121591-A1 | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 | KCNJ4, KCNK4, KCNQ4 | PTGS1 3442/4885PTGS2 3715/4885MGLL 3636/4885 |
| US-20150023988-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | SCN7A, SCN9A, SCN1A | PTGS1 2922/4885PTGS2 3218/4885MGLL 4337/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | PTGS1 3535/4885PTGS2 3850/4885MGLL 3340/4885 |
| US-20160024159-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | SCN7A, SCN9A, SCN1A | PTGS1 2922/4885PTGS2 3218/4885MGLL 4337/4885 |
| US-20160067347-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | APLNR, FABP3, AP2B1 | PTGS1 2699/4885PTGS2 2546/4885MGLL 3108/4885 |
| US-20160304570-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | PTGS1 3181/4885PTGS2 3564/4885MGLL 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.